Upon realizing the potential of this route of administration, industry stakeholders have initiated several R&D efforts focused on exploiting the use of intranasal therapeutics as an effective modality for the treatment of various disorders.
Roots Analysis has announced the addition of “Intranasal Drug Delivery Market” report to its list of offerings.
Over the last few years, pharmaceutical companies have expanded their focus to devise novel intranasal drug delivery systems for the development of therapeutic candidates. This can be attributed to its numerous advantages such as, ease of administration, avoidance of first pass-metabolism and rapid onset of action, potentially making it an appealing alternative to other drug delivery systems.
To order this 250+ page report, which features 120+ figures, please visit https://www.rootsanalysis.com/reports/intranasal-therapeutics-and-drug-delivery-systems.html
Key Market Insights
In addition to more than 10 approved products, over 65 drug candidates form a part of the development pipeline
Close to 60% of the pipeline candidates are currently being evaluated in clinical stages; of these, more than 15 drugs are in phase II studies. It is also worth highlighting that majority of the therapy candidates (55%) are small molecules.
~50 companies claim to be engaged in the development of intranasal therapeutics, globally
Of the total, 20% companies were established in this domain since 2016. Further, around 54% of the industry stakeholders are small companies. In addition, majority (80%) of the intranasal therapeutic developers are based in North America, primarily in the US.
Presently, more than 40 intranasal drug delivery systems are available across different regions
40% of the intranasal drug delivery systems are available in unit and multi dose type of systems. This is followed by 20% intranasal drug delivery systems have metered dose type of system. It is worth highlighting that majority of the intranasal drug delivery systems are (53%) are present in liquid type of dosage form.
More than 34,000 patients have been enrolled in over 130 clinical trials, worldwide
Clinical research activity, in terms of number of trials registered, is reported to have increased over the last five years. Of the total number of trials, close to 65% have already been completed, while 16% are active and still recruiting patients.
~ 400 patents focused on intranasal therapeutics and drug delivery systems have been published, globally
Owing to the rising research efforts of several industry and non-industry players engaged in this domain, close to 56% of patent applications have been filed post 2014. It is worth noting that, 235 patents related to intranasal therapeutics and drug delivery systems were filled / granted in the US alone.
Close to 50 partnerships have been inked among various industry and non-industry players between 2016 and 2021
Maximum number of partnerships were established in 2020, indicating a recent rise in the interest of players engaged in this domain. It is worth mentioning that, majority (19%) of the deals were instances of product commercialization / distribution agreements, followed by technology utilization agreements (17%).
Close to USD 5.5 billion has been invested by both private and public investors, since 2016
Of the total amount invested, over USD 1 billion was raised through debt financing, representing over 50% of the overall funding activity in this domain. Further, 11 instances of other equity were reported, wherein players collectively received funds worth more than USD 0.7 billion.
North America is anticipated to capture over 85% of the global market share, in 2035
The market will be primarily driven by sales of intranasal small molecule therapeutics (91%), followed by those developed as biologics (9%). Further, intranasal therapies targeting dry eye diseases are expected to capture the dominant share (64.8%) of the market (in terms of sales-based revenues); this trend is unlikely to change in the foreseen future as well.
To request a sample copy / brochure of this report, please visit link
Key Questions Answered
- Who are the key players engaged in offering intranasal therapeutics and drug delivery systems, across the world?
- What are the key therapeutic indications for which intranasal therapeutics are being investigated?
- What are the key geographies where research focused on intranasal therapeutics and drug delivery systems is being conducted?
- What kind of partnership models are most commonly adopted by stakeholders engaged in this industry?
- How is the current and future market opportunity likely to be distributed across key market segments?
- What are the anticipated future trends related to intranasal therapeutics and drug delivery systems market?
The financial opportunity within the intranasal therapeutics market has been analyzed across the following segments:
- Type of Molecule
- Small Molecules
- Biologics
- Target Indication
- Acute Repetitive Clusters
- Anaphylaxis
- COVID-19
- Dry Eye Disease
- Hypoglycemia
- Influenza
- Major Depressive Disorder
- Migraine
- Nasal Polyps
- Prader-Willi Syndrome
- Key Players
- Key Geographical Regions
- North America
- Europe
- Asia Pacific
The research also includes detailed profiles of the companies (listed below) engaged in developing intranasal therapeutics and drug delivery systems; each profile features an overview of the company, its financial information (if available), details on product portfolio, recent developments, and an informed future outlook.
- Aptar Pharma
- Nemera
- Teleflex
- Mystic Pharmaceuticals
- Zeteo Biomedical
For additional details, please visit
https://www.rootsanalysis.com/reports/intranasal-therapeutics-and-drug-delivery-systems.html or email sales@rootsanalysis.com
You may also be interested in the following titles:
- Single-use Sensors for Bioprocessing Market, 2021-2035
- At-Home Blood Collection and Micro Sampling Devices Market, 2021-2030
- Inhaled and Intranasal Products Contract Service Providers Market, 2020-2030
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
